Parameter
| Biomarker | NF2 Mut | Full name | NF2 Gene Mutation | Molecular Type | Gene Mutation |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Diagnosis, Prognosis, Risk Stratification |
| Disease | Meningioma | Disease Subtypes | / | ||
| Organ | Brain, Meninges | Test Sample / Technology Platform | Tumor Tissue/Plasma (NGS, Sanger Sequencing) | ||
| Pathobiological Mechanisms | Tumor suppressor gene inactivation leads to Merlin protein deficiency, activates the PI3K/AKT and Hippo pathways, and promotes tumor proliferation and invasion. | ||||
| Clinical Availability Status | Clinically Available | ||||
| Notes and Dynamics | Mutations are present in approximately 60%-70% of sporadic meningiomas; mutant types have a high recurrence rate, and FAK inhibitors show therapeutic potential in clinical trials. | ||||